[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundacion Dexeus\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":142},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,67,90,117],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100635739",false,"NCT07556601","Ultra-rapid Blastocyst Vitrification: Pilot Randomized Study","Clinical Validation of Ultra-rapid Blastocyst Vitrification: a Randomized Pilot Study in Oocyte Donation Cycles","Inclusion Criteria:\n\n* Recipients of donor oocytes\n* Blastocysts suitable for cryopreservation\n\nExclusion Criteria:\n\n* Cycles involving PGT\n* Cycles not reaching blastocyst stage.","FEMALE","18 Years","50 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach.",[26],"Infertility","RECRUITING","2026-06-29",{"date":30,"type":31},"2026-06-30","ACTUAL",{"date":33,"type":31},"2026-06-01",{"date":35,"type":20},"2028-03",{"name":37,"class":38},"Fundacion Dexeus","OTHER",2,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":5},"100574795","NCT06763926","Intranasal Nafarelin For Triggering Oocyte Maturation","Intranasal Nafarelin Compared to Subcutaneous Triptorelin for Triggering Final Oocyte Maturation in Ovarian Stimulation: a Non-inferiority Randomised Controlled Clinical Trial","INFORM","Inclusion Criteria:\n\n* Women undergoing fertility preservation cycles with oocyte cryopreservation\n* Undergoing a progesterone-primed ovarian stimulation cycle (PPOS) with any commercially available gonadotropin preparation(s)\n* BMI 18 - 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to either of the study drugs\n* Hypopituitarism\n* Known pituitary tumour\n* Contraindication to intranasal medication administration\n* Previous poor response to agonist trigger","40 Years",{"count":49,"type":20},154,[51],"PHASE4","This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.",[54],"Fertility Preservation",[56,57],"IVF","GnRH agonist","NOT_YET_RECRUITING","2026-06-02",{"date":61,"type":31},"2026-06-04",{"date":63,"type":20},"2026-06-15",{"date":65,"type":20},"2028-01-15",{"name":37,"class":38},{"id":68,"slug":4,"hasResults":10,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":5},"100632548","NCT07515118","AI-TOP Study Artificial Intelligence for Trigger Optimization.","An Artificial Intelligence Based Approach for Selecting the Optimal Day for Triggering.","AI-TOP","Inclusion Criteria:\n\n* Undergoing COS for IVF with autologous oocytes, oocyte donation and elective fertility preservation with all monitoring USS (ultrasound scan) conducted at our centers.\n\nExclusion Criteria:\n\n* Medically indicated fertility preservation\n* Inability to attend clinic visits for monitoring.","42 Years",{"count":76,"type":20},644,[23],"To evaluate, in a randomized controlled trial, whether AI-guided monitoring and ovulation triggering leads to clinical outcomes comparable to those achieved through physician-led decision-making in patients undergoing ovarian stimulation for IVF.",[26,80,81],"Ovarian Stimulation","Artificial Intelligence","2026-04-21",{"date":84,"type":31},"2026-04-22",{"date":86,"type":31},"2026-04-08",{"date":88,"type":20},"2027-09",{"name":37,"class":38},{"id":91,"slug":4,"hasResults":10,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100583442","NCT06876376","Intraoperative Ultrasound in Bowel Deep Endometriosis","Intraoperative Transvaginal and Endorectal Ultrasound for the Assessment of Bowel Deep Infiltrating Endometriosis","Inclusion Criteria:\n\n* Preoperative sonographic and\u002For MRI findings suggestive of bowel DIE (uterosacral ligaments, posterior vaginal wall, parametrium, retrocervical area, rectovaginal septum, rectum, and\u002For sigmoid colon).\n* Scheduled for surgical treatment (laparoscopy or robot-assisted laparoscopy).\n* Planned postoperative follow-up for at least 12 months.\n* Written informed consent provided before surgery.\n\nExclusion Criteria:\n\n* Planned surgery for diagnostic purposes only.\n* Pregnancy at the time of enrollment.\n* Poor understanding of Spanish or English.",{"count":97,"type":20},200,"OBSERVATIONAL","This study investigates the use of intraoperative transvaginal (IOTVUS) and\u002For endorectal ultrasound (IOERUS) in the surgical treatment of bowel deep infiltrating endometriosis (DIE).",[101],"Deep Infiltrating Endometriosis With or Without Bowel Involvement",[103,104,105,106,107],"Endometriosis","Intraoperative Ultrasound","Ultrasound","surgery","minimally invasive surgery","2026-03-25",{"date":110,"type":31},"2026-03-30",{"date":112,"type":31},"2025-01-20",{"date":114,"type":20},"2027-06",{"name":37,"class":38},1,{"id":118,"slug":4,"hasResults":10,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":141,"locationsCount":5},"100611588","NCT07242534","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.","Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. A Randomized Controlled Trial","SEQ","Inclusion Criteria:\n\n* ≤ 38 years\n* AMH \\>= 1 ng\u002FmL or AFC \\>= 6\n* Body mass index (BMI) between 27 kg\u002Fm2 and 40 kg\u002Fm2\n* Scheduled for IVF with freeze-all strategy\n\nExclusion Criteria:\n\n* Severe male factor (sperm concentration \\\u003C5M\u002FmL)\n* Type 2 diabetes mellitus\n* Prior use of GLP-1 Ras within the past year\n* Uncontrolled thyroid disorders\n* Contraindications to IVF or semaglutide treatment\n* Patients with chronic inflammatory diseases\n* Family history of hereditary or chromosomal diseases\n* Use of glucocorticoids or immunosuppressants\n* PGT-A\n* Use of medications affecting metabolism or inflammation","38 Years",{"count":126,"type":20},62,[51],"This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.",[26,130],"Obesity",[130,132,133,56,134],"Overweight","GLP-1 receptor agonist","ART","2026-01-19",{"date":137,"type":31},"2026-01-21",{"date":135,"type":31},{"date":140,"type":20},"2027-05",{"name":37,"class":38},""]